Detalles de la búsqueda
1.
Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
J Am Acad Dermatol
; 82(6): 1415-1421, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31541747
2.
An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
J Am Acad Dermatol
; 71(5): 904-911.e1, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24929884
3.
Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
J Clin Oncol
; 40(19): 2119-2127, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35333541
4.
Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
J Am Acad Dermatol
; 75(1): 213-5, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27317518
5.
Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry.
JAMA Dermatol
; 153(2): 189-192, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27902821
6.
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
JAMA Dermatol
; 152(4): 452-6, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26765315
7.
Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial.
JAMA Dermatol
; 155(9): 1078-1080, 2019 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339515
Resultados
1 -
7
de 7
1
Próxima >
>>